Article

Molecular mechanisms of β-lactam resistance in Streptococcus pneumoniae.

Department of Microbiology, University of Kaiserslautern, Paul Ehrlich Strasse 23, D-67663 Kaiserslautern, Germany.
Future Microbiology (Impact Factor: 3.82). 03/2012; 7(3):395-410. DOI: 10.2217/fmb.12.2
Source: PubMed

ABSTRACT Alterations in the target enzymes for β-lactam antibiotics, the penicillin-binding proteins (PBPs), have been recognized as a major resistance mechanism in Streptococcus pneumoniae. Mutations in PBPs that confer a reduced affinity to β-lactams have been identified in laboratory mutants and clinical isolates, and document an astounding variability of sites involved in this phenotype. Whereas point mutations are selected in the laboratory, clinical isolates display a mosaic structure of the affected PBP genes, the result of interspecies gene transfer and recombination events. Depending on the selective β-lactam, different combinations of PBP genes and mutations within are involved in conferring resistance, and astoundingly in non-PBP genes as well.

2 Followers
 · 
282 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The genus Streptococcus contains 104 recognized species, many of which are associated with human or animal hosts. A globally prevalent human pathogen in this group is Streptococcus pneumoniae (the pneumococcus). While being a common resident of the upper respiratory tract, it is also a major cause of otitis media, pneumonia, bacteremia and meningitis, accounting for a high burden of morbidity and mortality worldwide. Recent findings demonstrate the importance of recombination and selection in driving the population dynamics and evolution of different pneumococcal lineages, allowing them to successfully evade the impacts of selective pressures such as vaccination and antibiotic treatment. We highlight the ability of pneumococci to respond to these pressures through processes including serotype replacement, capsular switching and horizontal gene transfer (HGT) of antibiotic resistance genes. The challenge in controlling this pathogen also lies in the exceptional genetic and phenotypic variation among different pneumococcal lineages, particularly in terms of their pathogenicity and resistance to current therapeutic strategies. The widespread use of pneumococcal conjugate vaccines, which target only a small subset of the more than 90 pneumococcal serotypes, provides us with a unique opportunity to elucidate how the processes of selection and recombination interact to generate a remarkable level of plasticity and heterogeneity in the pneumococcal genome. These processes also play an important role in the emergence and spread of multi-resistant strains, which continues to pose a challenge in disease control and/or eradication. The application of population of genomic approaches at different spatial and temporal scales will help improve strategies to control this global pathogen, and potentially other pathogenic streptococci.
    Infection Genetics and Evolution 11/2014; DOI:10.1016/j.meegid.2014.11.007 · 3.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Review current knowledge on natural transformation in Streptococcus pneumoniae.•Review all aspects of this process with emphasis on a DNA-acquisition mechanism termed fratricide.•Focus on the ecology of natural transformation, i.e. the least known aspect of this process.•Discuss how external stress such as antimicrobial therapy and vaccination drives genome evolution in S. pneumoniae through natural transformation.
    Infection Genetics and Evolution 11/2014; DOI:10.1016/j.meegid.2014.10.020 · 3.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Understanding of antibiotic resistance in Streptococcus pneumoniae has been hindered by the low frequency of recombination events in bacteria and thus the presence of large linked haplotype blocks, which preclude identification of causative variants. A recent study combining a large number of genomes of resistant phenotypes has given an insight into the evolving resistance to β-lactams, providing the first large-scale identification of candidate variants underlying resistance.
    Genome Medicine 09/2014; 6(9):72. DOI:10.1186/s13073-014-0072-8 · 4.94 Impact Factor